Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX6 + tislelizumab + bevacizumab in previously treated metastatic hepatocellular carcinoma
ChiCTR2400090013Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, fluorouracil, bevacizumab and tislelizumab in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Median progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
oxaliplatinfolinic acidfluorouracilbevacizumabtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400090013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090013.